Cook Medical wins CE mark for PVA Foam Embolisation Particles

1 May 2013 (Last Updated May 1st, 2013 18:30)

The European Union (EU) has granted CE mark certification to Cook Medical's PVA foam embolisation particles for the treatment of symptomatic benign prostatic hyperplasia (BPH).

The European Union (EU) has granted CE mark certification to Cook Medical's PVA foam embolisation particles for the treatment of symptomatic benign prostatic hyperplasia (BPH).

Also known as prostate enlargement, BPH can lead to lower urinary tract symptoms and is expected to affect more than 50% of men by the time they reach 60 years of age.

BPH, which is commonly treated with surgery, can also be treated with a minimally-invasive alternative procedure, prostatic artery embolisation (PAE).

"BPH, which is commonly treated with surgery, can also be treated with a minimally-invasive alternative procedure, prostatic artery embolisation (PAE)."

The procedure involves injecting small particles, such as Cook's PVA particles, into the blood vessels that supply the prostate, which block the blood so that it doesn't reach the overgrown prostatic tissue.

Blocking the blood reduces the size of the prostate and relieves symptoms, according to the company.

The PVA foam embolisation particles have also shown positive short and midterm results and provided durable relief of BPH symptoms in a global patient trial, which the company claims is the largest trial to date.

Cook Medical peripheral intervention division vice president and global leader Rob Lyles said; "We have worked hard to offer our PVA foam embolisation particles for PAE as option for the millions of men suffering from symptoms of BPH," Lyles added.